Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 8/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8766421 | 0.81 | TAAR1 (0.57) | MTNR1AMTNR1BMEN1KMT2A | |
| SCHEMBL21225979 | 0.80 | ALOX5 (0.57) | ALOX5CYP3A4LMNAPARP1ACHE | |
| SCHEMBL715536 | 0.80 | CYP3A4 (0.56) | CYP3A4LMNAPARP1ACHECNR2 | |
| SCHEMBL1561685 | 0.80 | CYP3A4 (0.56) | CYP3A4LMNAPARP1ACHEMTNR1A | |
| SCHEMBL3898374 | 0.79 | CHRM2 (0.56) | ALOX5CYP3A4LMNAMEN1KMT2A | |
| SCHEMBL13314605 | 0.78 | ALDH1A1 (0.55) | CYP3A4LMNAPARP1ACHEMTNR1A | |
| SCHEMBL715236 | 0.78 | LMNA (0.54) | CYP3A4LMNAPARP1ACHEMTNR1A | |
| SCHEMBL7613234 | 0.78 | CYP3A4 (0.54) | ALOX5CYP3A4LMNAPARP1ACHE | |
| SCHEMBL27348013 | 0.78 | ACHE (0.70) | CYP3A4LMNAPARP1ACHEMTNR1A | |
| SCHEMBL3407357 | 0.78 | CYP3A4 (0.58) | CYP3A4LMNAPARP1ACHEMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745438-B2 | 3-(2-acylamino-1-hydroxyethyl)-morpholine derivatives and their use as bace inhibitors | ELI LILLY AND COMPANY (US) | 2010-06-29 | — | — | US | disclosed |
| EP-2091928-A2 | 3-(2-ACYLAMINO-1-HYDROXYETHYL)- MORPHOLINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20070225267-A1 | 3-(2-Acylamino-1-Hydroxyethyl)-Morpholine Derivatives and Their Use as Bace Inhibitors | ELI LILLY AND COMPANY | 2007-09-27 | — | — | US | disclosed |
| WO-2006034093-A2 | 3- (2-ACYLAMINO-1-HYDROXYETHYL)- MORPHOLINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS | ELLI LILLY AND COMPANY (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225267-A1 | 3-(2-Acylamino-1-Hydroxyethyl)-Morpholine Derivatives and Their Use as Bace Inhibitors | BACE1, BACE2, APP | ALOX5 2689/4885CYP3A4 423/4885LMNA 877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.